2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1346

Leveraging Electronic Health Records to Improve Vaccination Rates for Patients with Rheumatoid Arthritis
Abstract Number: 2351

Ligand of Glucocorticoid-Induced Tumor Necrosis Factor Receptor Enhances Th17 Cells Response in Collagen-Induced Arthritis Via P38 MAPK and STAT3 Pathway
Abstract Number: 2137

Linear Extrapolation of Missing Radiographic Progression Scores Does Not Spuriously overestimate overall Radiographic Progression in Rheumatoid Arthritis
Abstract Number: 399

Lipid Concentrations and Particle Sizes in Drug Naive Patients with Rheumatoid Arthritis
Abstract Number: 841

Lipid Control and Cardiovascular Risk for Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients
Abstract Number: 636

Liposomal-Glucocorticoids: A Novel Approach to the Therapy of SLE
Abstract Number: 92

Long Noncoding RNA Nron Regulates the Activity of NFAT5 through Ubiquitin-Independent Proteasome Pathway in Rheumatoid Arthritis
Abstract Number: 293

Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Abstract Number: 1559

Long Term Improvements in Physical Function Are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients
Abstract Number: 1245

Long Term Outcome of Infliximab in Severe and Refractory Systemic Sarcoidosis: Report of 16 Cases
Abstract Number: 913

Long Term Outcomes of Patients with Moderate Creatine Kinase (CK) Elevation Seen in a Rheumatology Clinic
Abstract Number: 174

Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study
Abstract Number: 479

Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years
Abstract Number: L22

Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)
Abstract Number: 1564

Long-Term (104-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial and Open-Label Extension

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].